Earnings Preview For Inovio Pharmaceuticals

Inovio Pharmaceuticals INO releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Inovio Pharmaceuticals' earnings report.

Earnings and Revenue

Wall Street analysts see Inovio Pharmaceuticals reporting a loss of 30 cents per share on revenue of $7.5 million.

Inovio Pharmaceuticals EPS in the same period a year ago came in at a loss of 35 cents. Sales were $8.5 million. If the company were to match the consensus estimate, earnings would be up 14.29 percent. Revenue would be down 11.56 percent from the year-ago period.

In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.25 -0.19 -0.31 -0.3
EPS Actual -0.4 -0.13 -0.31 -0.35

 

Stock Performance

Over the last 52-week period, shares are down 32.24 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Inovio Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

The Inovio Pharmaceuticals's Q4 conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here: http://ir.inovio.com/news-and-media/news/default.aspx

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPreviewsTrading IdeasEarnings Previews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...